Stock ATOS ATOSSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
1.53 USD +1.32% Intraday chart for Atossa Therapeutics, Inc. +2.00% +73.86%
Apr. 29 Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen CI
Apr. 15 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors
CI
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
CI
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors
CI
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors
CI
Atossa Therapeutics, Inc. Announces Resignation of Greg Weaver as Executive Vice President
CI
Atossa Therapeutics Names Greg Weaver Chief Financial Officer
MT
Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer
CI
Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board
CI
Insider Trends: Atossa Therapeutics Insider Exercises Options Derivative Securities, Sells for Taxes and Self, Selling Trend Unaffected
MT
Atossa Therapeutics, Inc. Announces Management Changes
CI
Atossa Genetics Inc. has Changed its Name to Atossa Therapeutics, Inc
CI
Atossa Genetics Inc. Announces Board Changes
CI
Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth
CI
Atossa Genetics Appoints Per Hall as Scientific Advisor
CI
Atossa Genetics Inc. Appoints Carl Novina, as Scientific Advisor
CI
Atossa Genetics Appoints Jack Cuzick as Scientific Advisor
CI
Atossa Genetics Announces Resignation of Scott Youmans as a Chief Operating Officer, Effective February 12, 2016
CI
Atossa Genetics, Inc. Appoints Janet Rose Rea as VP Regulatory Affairs and Quality
CI
Atossa Genetics, Inc. Appoints Scott Youmans as Chief Operating Officer
CI
John E. Sawyer Resigns as Senior Vice President, Global Regulatory Affairs and Quality Assurance, of Atossa Genetics Inc, Effective June 8, 2015
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATOS Stock
  4. News Atossa Therapeutics, Inc.
  5. Insiders